Given the patient’s history of CLL, those B-cell aggregates were further evaluated for potential SLL deposits and demonstrated positivity for CD20, CD5, and LEF-1 (weak positivity), being most consistent with CLL/SLL as opposed to tumor-associated TLS (Figure 3d). This evidence concerns the gene CD5 and neoplasm.